AR082967A1 - FORMULATIONS OF HISTONA DEACETILASE INHIBITOR IN COMBINATION WITH BENDAMUSTINE AND USE OF THE SAME, TREATMENT METHOD - Google Patents

FORMULATIONS OF HISTONA DEACETILASE INHIBITOR IN COMBINATION WITH BENDAMUSTINE AND USE OF THE SAME, TREATMENT METHOD

Info

Publication number
AR082967A1
AR082967A1 ARP110103321A AR082967A1 AR 082967 A1 AR082967 A1 AR 082967A1 AR P110103321 A ARP110103321 A AR P110103321A AR 082967 A1 AR082967 A1 AR 082967A1
Authority
AR
Argentina
Prior art keywords
bendamustine
combination
pharmaceutically acceptable
hdac inhibitor
inhibitor
Prior art date
Application number
Other languages
Spanish (es)
Inventor
Erik J Verner
Norbert Purro
Sriram Balasubramanian
David J Loury
Joseph J Buggy
Tarak D Mody
Original Assignee
Pharmacyclics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacyclics Inc filed Critical Pharmacyclics Inc
Priority to ARP110103321 priority Critical patent/AR082967A1/en
Publication of AR082967A1 publication Critical patent/AR082967A1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Reivindicación 1: Una composición farmacéutica que comprende bendamustina y un inhibidor de HDAC en donde la combinación es adecuada para administración separada, secuencial y/o simultánea.Reivindicación 2: Una composición farmacéutica en una forma de dosificación sólida adecuada para administración oral, la composición comprende: un ingrediente activo que es el compuesto de fórmula (1) o una sal farmacéuticamente aceptable del mismo; un segundo ingrediente activo que es bendamustina o un éster, sal o solvato farmacéuticamente aceptable del mismo; y por lo menos un excipiente farmacéuticamente aceptable. Reivindicación 3: La composición farmacéutica de las reivindicaciones 19 - 20, en donde dicha composición es una composición farmacéutica sólida oral de liberación controlada. Reivindicación 9: Combinación de bendamustina y un inhibidor de HDAC. Reivindicación 10: La combinación de acuerdo con la reivindicación 9, en donde el inhibidor de HDAC es el compuesto de fórmula (1) o una sal farmacéuticamente aceptable del mismo. Reivindicación 27: El método como se reivindica en las reivindicaciones 11 - 26, en donde el inhibidor de HDAC es la sal HCI de N-hidroxi-4-{2-[3-(N,N-dimetilaminometil)benzofuran-2-ilcarbonilamino]etoxi}-benzamida.Claim 1: A pharmaceutical composition comprising bendamustine and an HDAC inhibitor wherein the combination is suitable for separate, sequential and / or simultaneous administration. Claim 2: A pharmaceutical composition in a solid dosage form suitable for oral administration, the composition comprises : an active ingredient that is the compound of formula (1) or a pharmaceutically acceptable salt thereof; a second active ingredient that is bendamustine or a pharmaceutically acceptable ester, salt or solvate thereof; and at least one pharmaceutically acceptable excipient. Claim 3: The pharmaceutical composition of claims 19-20, wherein said composition is an oral solid pharmaceutical controlled release composition. Claim 9: Combination of bendamustine and an HDAC inhibitor. Claim 10: The combination according to claim 9, wherein the HDAC inhibitor is the compound of formula (1) or a pharmaceutically acceptable salt thereof. Claim 27: The method as claimed in claims 11-26, wherein the HDAC inhibitor is the HCI salt of N-hydroxy-4- {2- [3- (N, N-dimethylaminomethyl) benzofuran-2-ylcarbonylamino ] ethoxy} -benzamide.

ARP110103321 2011-09-13 2011-09-13 FORMULATIONS OF HISTONA DEACETILASE INHIBITOR IN COMBINATION WITH BENDAMUSTINE AND USE OF THE SAME, TREATMENT METHOD AR082967A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ARP110103321 AR082967A1 (en) 2011-09-13 2011-09-13 FORMULATIONS OF HISTONA DEACETILASE INHIBITOR IN COMBINATION WITH BENDAMUSTINE AND USE OF THE SAME, TREATMENT METHOD

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ARP110103321 AR082967A1 (en) 2011-09-13 2011-09-13 FORMULATIONS OF HISTONA DEACETILASE INHIBITOR IN COMBINATION WITH BENDAMUSTINE AND USE OF THE SAME, TREATMENT METHOD

Publications (1)

Publication Number Publication Date
AR082967A1 true AR082967A1 (en) 2013-01-23

Family

ID=48485809

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110103321 AR082967A1 (en) 2011-09-13 2011-09-13 FORMULATIONS OF HISTONA DEACETILASE INHIBITOR IN COMBINATION WITH BENDAMUSTINE AND USE OF THE SAME, TREATMENT METHOD

Country Status (1)

Country Link
AR (1) AR082967A1 (en)

Similar Documents

Publication Publication Date Title
CR20150628A (en) DERIVATIVES OF PIRAZOLOPIRROLIDINE AND ITS USE IN THE TREATMENT OF DISEASES
PE20142353A1 (en) NORIBOGAINE SALT ANSOLVATES
CO6470846A2 (en) AMINOBUTICAL DERIVATIVES REPLACED AS NEPRILISINE INHIBITORS
AR089578A1 (en) COMPOSITIONS, METHODS TO TREAT HEPATITIS C VIRUS AND PREPARATION PROCESS
CL2018001510A1 (en) Pharmaceutical composition comprising a potent urat1 inhibitor
SV2009002857A (en) SOLID PHARMACEUTICAL PRESENTATION FORMS OF ORAL ADMINISTRATION WITH QUICK RELEASE OF ACTIVE PRINCIPLE
SV2010003451A (en) PIRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES
CL2011002858A1 (en) Use of an oral transmucosal pharmaceutical composition comprising dexmedetomidine and a pharmaceutically acceptable salt and a pharmaceutically acceptable excipient to prepare a medicament useful for treating or preventing pain.
CO6491060A2 (en) COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITARY DISEASES
PE20140255A1 (en) DISPERSIBLE TABLET IN ORAL FORM
BRPI0922806B8 (en) oral pharmaceutical composition comprising bendamustine
CO6640318A2 (en) Oral dosage forms of bendamustine
CO2019004004A2 (en) Pharmaceutical composition and method for the treatment of non-alcoholic fatty liver disease
CL2010000524A1 (en) Use of a topical composition comprising 3.75% imiquimod and a pharmaceutically acceptable carrier to prepare a medicament useful for treating genital or perianal warts.
CL2015002466A1 (en) Organic compound formulations
UY31768A (en) USE OF DRONEDARONE OR A PHARMACEUTICALLY ACCEPTABLE SALT OF THIS, FOR THE PREPARATION OF A MEDICINAL PRODUCT TO REGULATE THE LEVEL OF POTASSIUM IN THE BLOOD
UY30847A1 (en) USE OF DIANHYDROHEXITE MONONITRATE DERIVATIVES AS AGENTS FOR THE TREATMENT OF INTESTINAL DISORDERS
AR087787A1 (en) BENZOTIAZOLONA COMPOSITE
UY33745A (en) DIFENYLAMINE DERIVATIVES: USES, SYNTHESIS PROCEDURE AND PHARMACEUTICAL COMPOSITIONS
AR086491A1 (en) PHARMACEUTICAL COMPOSITION INCLUDING FEXOFENADINE
GT201000064A (en) ALISQUIREN GALENIC FORMULATIONS
ECSP13012369A (en) THERAPEUTIC AGENTS 976
UY35323A (en) SUBSTITUTED DERIVATIVES OF BUTANOLIC BISPHENILE ACID AS INHIBITORS OF THE NEP WITH AN IMPROVED EFFICIENCY IN VIVO
AR082967A1 (en) FORMULATIONS OF HISTONA DEACETILASE INHIBITOR IN COMBINATION WITH BENDAMUSTINE AND USE OF THE SAME, TREATMENT METHOD
CO6460763A2 (en) ECTOPARASITICID METHODS AND FORMULATIONS

Legal Events

Date Code Title Description
FB Suspension of granting procedure